The FDA granted Fast Track designation to CT-0508, a human epidermal growth factor receptor 2 targeted chimeric antigen receptor macrophage for the treatment of patients with solid tumors.
The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score ≥ 5.
The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of Keytruda (pembrolizumab), an anti-PD-1 therapy, in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumors express PD-L1 (Combined Positive Score ≥10) and who have not received prior chemotherapy for metastatic disease.
John A. Ellerton, the principal investigator of the Nevada Cancer Research Foundation NCI Community Oncology Research Program, has won the 2021 Harry Hynes Award. The award is given annually to NCORP PIs for outstanding contribution to clinical trials and community research. In 1983, Ellerton’s group, then called the Southern Nevada Research Foundation, was among the... […]
Seven clinicians and researchers were named to the National Cancer Advisory Board.
Michelle M. Le Beau was named chief scientific officer of the Cancer Prevention and Research Institute of Texas.
Tracy Gosselin was named senior vice president, chief nurse executive, and chair of nursing at Memorial Sloan Kettering Cancer Center, effective November.
Renier Brentjens was named deputy director, the Katherine Anne Gioia Endowed Chair in Cancer Medicine, chair of the Department of Medicine, and professor of oncology in the Departments of Medicine and Immunology at Roswell Park Comprehensive Cancer Center.
Researchers from Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center have received a nearly $9 million SPORE grant from NCI to develop new and better treatments for ovarian cancer.
The American Association for Cancer Research has established its eighth scientific working group, which is dedicated to supporting cancer prevention research.
